Table 4.
c in years | treatment | total0 | age0 | gender | ν (θ̂|c, d = 3, z) | ν (θ̂|c, d = 6, z) |
---|---|---|---|---|---|---|
1.0 | Placebo | 16 | 55 | Female | 0.378 | 0.469 |
1.0 | Placebo | 16 | 55 | Male | 0.425 | 0.524 |
1.0 | Placebo | 16 | 69 | Female | 0.342 | 0.428 |
1.0 | Placebo | 16 | 69 | Male | 0.399 | 0.494 |
1.0 | Placebo | 25 | 55 | Female | 0.323 | 0.404 |
1.0 | Placebo | 25 | 55 | Male | 0.372 | 0.462 |
1.0 | Placebo | 25 | 69 | Female | 0.279 | 0.352 |
1.0 | Placebo | 25 | 69 | Male | 0.343 | 0.428 |
1.0 | Deprenyl | 16 | 55 | Female | 0.395 | 0.489 |
1.0 | Deprenyl | 16 | 55 | Male | 0.444 | 0.546 |
1.0 | Deprenyl | 16 | 69 | Female | 0.357 | 0.444 |
1.0 | Deprenyl | 16 | 69 | Male | 0.409 | 0.505 |
1.0 | Deprenyl | 25 | 55 | Female | 0.328 | 0.410 |
1.0 | Deprenyl | 25 | 55 | Male | 0.385 | 0.478 |
1.0 | Deprenyl | 25 | 69 | Female | 0.297 | 0.374 |
1.0 | Deprenyl | 25 | 69 | Male | 0.349 | 0.435 |
1.5 | Placebo | 16 | 55 | Female | 0.296 | 0.374 |
1.5 | Placebo | 16 | 55 | Male | 0.340 | 0.427 |
1.5 | Placebo | 16 | 69 | Female | 0.268 | 0.340 |
1.5 | Placebo | 16 | 69 | Male | 0.305 | 0.386 |
1.5 | Placebo | 25 | 55 | Female | 0.241 | 0.307 |
1.5 | Placebo | 25 | 55 | Male | 0.286 | 0.362 |
1.5 | Placebo | 25 | 69 | Female | 0.220 | 0.282 |
1.5 | Placebo | 25 | 69 | Male | 0.254 | 0.323 |
1.5 | Deprenyl | 16 | 55 | Female | 0.305 | 0.384 |
1.5 | Deprenyl | 16 | 55 | Male | 0.353 | 0.442 |
1.5 | Deprenyl | 16 | 69 | Female | 0.280 | 0.354 |
1.5 | Deprenyl | 16 | 69 | Male | 0.330 | 0.415 |
1.5 | Deprenyl | 25 | 55 | Female | 0.260 | 0.329 |
1.5 | Deprenyl | 25 | 55 | Male | 0.304 | 0.383 |
1.5 | Deprenyl | 25 | 69 | Female | 0.229 | 0.292 |
1.5 | Deprenyl | 25 | 69 | Male | 0.280 | 0.354 |